Sugi Predict

Sugi Predict / Compounds / SCHEMBL16009256

SCHEMBL16009256

SCHEMBL16009256

CS(=O)(=O)Cc1ccc(Nc2ccc(F)cc2F)c(Br)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 7/20 0.51
▸ SOS1 Q07889 1/20 0.45
▸ PTGS2 P35354 1/20 0.41
▸ GAA P10253 1/20 0.40
▸ ZAP70 P43403 1/20 0.40
▸ THRB P10828 1/20 0.39
▸ BRD2 P25440 1/20 0.38
▸ BRD3 Q15059 1/20 0.38
▸ BRDT Q58F21 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ GSK3A P49840 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ IRAK1 P51617 1/20 0.38
▸ CNR1 P21554 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ PTPN1 P18031 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17492772 0.86 SOS1 (0.48) BRD4SOS1PTGS2GAAZAP70
SCHEMBL17492516 0.85 BRD4 (0.50) BRD4SOS1PTGS2CA12CA1
SCHEMBL16009168 0.82 SOS1 (0.58) BRD4SOS1PTGS2GAACA12
SCHEMBL16009461 0.80 BRD4 (0.50) BRD4SOS1PTGS2GAABRD2
SCHEMBL17492654 0.79 SOS1 (0.55) SOS1PTGS2ZAP70THRBCA12
SCHEMBL16010183 0.78 CNR1 (0.39) BRD4SOS1PTGS2GAATHRB
SCHEMBL21191092 0.76 BRD4 (0.48) BRD4PTGS2GAATHRBCA1
SCHEMBL21190843 0.76 BRD4 (0.45) BRD4SOS1PTGS2GAABRD2
SCHEMBL21191051 0.76 PTPN1 (0.45) BRD4CA1CA2CA9PTPN1
SCHEMBL30443821 0.76 EPAS1 (0.55) BRD4PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070756-A1 TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC (US) 2021-03-11 — — US disclosed
US-20200291027-A1 TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC (US) 2020-09-17 — — US disclosed
EP-3539962-A1 TETRACYCLIC BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2019-09-18 — — EP disclosed
WO-2019141131-A1 BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF 中国科学院上海药物研究所 2019-07-25 — — WO disclosed
EP-2970330-B1 TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC (US) 2019-04-17 — — EP disclosed
EP-2970285-B1 FUSED TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC (US) 2019-04-17 — — EP disclosed
US-20180298003-A1 TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC (US) 2018-10-18 — — US disclosed
US-10035800-B2 Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors ABBVIE INC. (US) 2018-07-31 — — US disclosed
US-20160237084-A1 DIHYDRO-PYRROLOPYRIDINONE INHIBITORS ABBVIE INC (US) 2016-08-18 — — US disclosed
US-9321764-B2 Dihydro-pyrrolopyridinone inhibitors ABBVIE INC. (US) 2016-04-26 — — US disclosed
US-20160039821-A1 TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC. 2016-02-11 — — US disclosed
EP-2970285-A1 FUSED TETRACYCLIC BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-01-20 — — EP disclosed
EP-2970276-A1 DIHYDRO-PYRROLOPYRIDINONE BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-01-20 — — EP disclosed
US-20150150884-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2015-06-04 — — US disclosed
US-8980879-B2 Bromodomain inhibitors ABBVIE INC. (US) 2015-03-17 — — US disclosed
WO-2014165143-A1 DIHYDRO-PYRROLOPYRIDINONE BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-10-09 — — WO disclosed
WO-2014164780-A1 FUSED TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-10-09 — — WO disclosed
US-20140275026-A1 DIHYDRO-PYRROLOPYRIDINONE INHIBITORS ABBVIE INC. 2014-09-18 — — US disclosed
US-20140256710-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10035800-B2 Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors BRD1, BRD3, BRD4 BRD4 3/4885SOS1 4702/4885PTGS2 1711/4885
US-20180298003-A1 TETRACYCLIC BROMODOMAIN INHIBITORS BRD3, BRD4, BRD1 BRD4 2/4885SOS1 4456/4885PTGS2 1360/4885
US-20200291027-A1 TETRACYCLIC BROMODOMAIN INHIBITORS BRD3, BRD4, BRD1 BRD4 2/4885SOS1 4456/4885PTGS2 1360/4885
US-20210070756-A1 TETRACYCLIC BROMODOMAIN INHIBITORS BRD3, BRD4, BRD1 BRD4 2/4885SOS1 4456/4885PTGS2 1360/4885
US-20150150884-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 BRD4 1/4885SOS1 4358/4885PTGS2 1218/4885
US-20160039821-A1 TETRACYCLIC BROMODOMAIN INHIBITORS BRD3, BRD4, BRD1 BRD4 2/4885SOS1 4402/4885PTGS2 1264/4885
US-20160237084-A1 DIHYDRO-PYRROLOPYRIDINONE INHIBITORS DPYD, QDPR, DHFR BRD4 676/4885SOS1 4401/4885PTGS2 840/4885
US-20140256710-A1 BROMODOMAIN INHIBITORS BRD4, BRD3, BRD1 BRD4 1/4885SOS1 4358/4885PTGS2 1218/4885
US-20140275026-A1 DIHYDRO-PYRROLOPYRIDINONE INHIBITORS DPYD, QDPR, DHFR BRD4 676/4885SOS1 4401/4885PTGS2 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.